AR and benign prostatic hyperplasia: As binding of DHT with androgen receptor induces increased synthesis of androgen-related proteins and growth factors and inhibits apoptosis, inhibition of DHT and its binding to the androgen receptor is considered a piotal therapeutic target in BPH treatment [16].